These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 33333889)

  • 21. Adverse Drug Reactions Reported With Cholinesterase Inhibitors: An Analysis of 16 Years of Individual Case Safety Reports From VigiBase.
    Kröger E; Mouls M; Wilchesky M; Berkers M; Carmichael PH; van Marum R; Souverein P; Egberts T; Laroche ML
    Ann Pharmacother; 2015 Nov; 49(11):1197-206. PubMed ID: 26324356
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparative Safety of Targeted Therapies for Metastatic Colorectal Cancer between Elderly and Younger Patients: a Study Using the International Pharmacovigilance Database.
    Gouverneur A; Claraz P; Rousset M; Arnaud M; Fourrier-Réglat A; Pariente A; Aparicio T; Miremont-Salamé G; Noize P
    Target Oncol; 2017 Dec; 12(6):805-814. PubMed ID: 29022151
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Adverse drug reactions during hepatitis C treatment with direct-acting antivirals: The role of medication errors, their impact on treatment discontinuation and their preventability. New insights from the Campania Region (Italy) spontaneous reporting system.
    Sessa M; Bernardi FF; Vitale A; Schiavone B; Gritti G; Mascolo A; Bertini M; Scavone C; Sportiello L; Rossi F; Capuano A
    J Clin Pharm Ther; 2018 Dec; 43(6):867-876. PubMed ID: 30014479
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of multiple sclerosis disease-modifying therapies on employment measures using patient-reported data.
    Chen J; Taylor BV; Blizzard L; Simpson S; Palmer AJ; van der Mei IAF
    J Neurol Neurosurg Psychiatry; 2018 Nov; 89(11):1200-1207. PubMed ID: 29921609
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A 7-Years Active Pharmacovigilance Study of Adverse Drug Reactions Causing Children Admission to a Pediatric Emergency Department in Sicily.
    Nasso C; Mecchio A; Rottura M; Valenzise M; Menniti-Ippolito F; Cutroneo PM; Squadrito V; Squadrito F; Pallio G; Irrera N; Arcoraci V; Altavilla D
    Front Pharmacol; 2020; 11():1090. PubMed ID: 32765282
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Characterization of serious adverse drug reactions as cause of emergency department visit in children: a 5-years active pharmacovigilance study.
    Lombardi N; Crescioli G; Bettiol A; Marconi E; Vitiello A; Bonaiuti R; Calvani AM; Masi S; Lucenteforte E; Mugelli A; Giovannelli L; Vannacci A
    BMC Pharmacol Toxicol; 2018 Apr; 19(1):16. PubMed ID: 29661234
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The importance of monitoring adverse drug reactions in elderly patients: the results of a long-term pharmacovigilance programme.
    Carnovale C; Gentili M; Fortino I; Merlino L; Clementi E; Radice S; ViGer Group
    Expert Opin Drug Saf; 2016; 15(2):131-9. PubMed ID: 26882049
    [TBL] [Abstract][Full Text] [Related]  

  • 28. FarmaREL: An Italian pharmacovigilance project to monitor and evaluate adverse drug reactions in haematologic patients.
    Fracchiolla NS; Artuso S; Cortelezzi A; Pelizzari AM; Tozzi P; Bonfichi M; Bocchio F; Gargantini L; De Rosa E; Vighi GD; Prestini L; Sammassimo S; Frungillo N; Pasquini MC; Ragazzi A; Boghi D; Pastore A; Lanzi E; Gritti G; Quaresmini G; Voltolini S; Gaiardoni R; Corti C; Vilardo MC; La Targia ML; Berini G; Magagnoli M; Bacci C; Consonni D; Rivolta AL; Muti G
    Hematol Oncol; 2018 Feb; 36(1):299-306. PubMed ID: 28771763
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Safety profile of etifoxine: A French pharmacovigilance survey.
    Cottin J; Gouraud A; Jean-Pastor MJ; Dautriche AD; Boulay C; Geniaux H; Auffret M; Bernard N; Descotes J; Vial T
    Fundam Clin Pharmacol; 2016 Apr; 30(2):147-52. PubMed ID: 26588183
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Established disease-modifying treatments in relapsing-remitting multiple sclerosis.
    Oh J; O'Connor PW
    Curr Opin Neurol; 2015 Jun; 28(3):220-9. PubMed ID: 25923124
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Adverse drug reactions reporting by undergraduate medical students in a tertiary care teaching hospital of India: Content and quality analysis in comparison to physician reporting.
    Patel PB; Patel TK; Anturlikar S; Khatun S; Bhabhor P; Saurabh MK
    Perspect Clin Res; 2017; 8(3):137-144. PubMed ID: 28828309
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Severe injection site reactions after subcutaneous administration of Sayana©.
    Jödicke AM; Dahmke H; Damke B; Schäublin M; Kullak-Ublick GA; Weiler S
    Swiss Med Wkly; 2017; 147():w14432. PubMed ID: 28634970
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Descriptions of Adverse Drug Reactions Are Less Informative in Forums Than in the French Pharmacovigilance Database but Provide More Unexpected Reactions.
    Karapetiantz P; Bellet F; Audeh B; Lardon J; Leprovost D; Aboukhamis R; Morlane-Hondère F; Grouin C; Burgun A; Katsahian S; Jaulent MC; Beyens MN; Lillo-Le Louët A; Bousquet C
    Front Pharmacol; 2018; 9():439. PubMed ID: 29765326
    [No Abstract]   [Full Text] [Related]  

  • 34. Adverse Drug Reactions in Hospitalized Patients: Results of the FORWARD (Facilitation of Reporting in Hospital Ward) Study.
    Giardina C; Cutroneo PM; Mocciaro E; Russo GT; Mandraffino G; Basile G; Rapisarda F; Ferrara R; Spina E; Arcoraci V
    Front Pharmacol; 2018; 9():350. PubMed ID: 29695966
    [No Abstract]   [Full Text] [Related]  

  • 35. Treatment satisfaction across injectable, infusion, and oral disease-modifying therapies for multiple sclerosis.
    Eagle T; Stuart F; Chua AS; LaRussa A; Leclaire K; Cook SL; Chitnis T; Weiner HL; Glanz BI; Healy BC
    Mult Scler Relat Disord; 2017 Nov; 18():196-201. PubMed ID: 29141809
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A survey of spontaneous reporting of adverse drug reactions in 10 years of activity in a pharmacovigilance centre in Portugal.
    Marques J; Ribeiro-Vaz I; Pereira AC; Polónia J
    Int J Pharm Pract; 2014 Aug; 22(4):275-82. PubMed ID: 24188533
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Does spontaneous adverse drug reactions' reporting differ between different reporters? A study in Toulouse Pharmacovigilance Centre.
    Nicol C; Moulis F; Bondon-Guitton E; Durrieu G; Montastruc JL; Bagheri H
    Therapie; 2019 Oct; 74(5):521-525. PubMed ID: 31029402
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Campania Preventability Assessment Committee (Italy): A Focus on the Preventability of Non-steroidal Anti-inflammatory Drugs' Adverse Drug Reactions.
    Sessa M; Sportiello L; Mascolo A; Scavone C; Gallipoli S; di Mauro G; Cimmaruta D; Rafaniello C; Capuano A
    Front Pharmacol; 2017; 8():305. PubMed ID: 28603499
    [No Abstract]   [Full Text] [Related]  

  • 39. Management of multiple sclerosis and the integration of related specialty pharmacy programs within health systems.
    Habibi M; Kuttab HM
    Am J Health Syst Pharm; 2016 Jun; 73(11):811-9. PubMed ID: 27126827
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Adverse psychiatric effects of disease-modifying therapies in multiple Sclerosis: A systematic review.
    Gasim M; Bernstein CN; Graff LA; Patten SB; El-Gabalawy R; Sareen J; Bolton JM; Marriott JJ; Fisk JD; Marrie RA;
    Mult Scler Relat Disord; 2018 Nov; 26():124-156. PubMed ID: 30248593
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.